Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Decreased Fc fucosylation aligns with enhanced RSV-specific antibody functionality in adults compared to young children

ABSTRACT: Respiratory syncytial virus (RSV) is a major cause of severe respiratory tract infections in infants and older adults. While vaccines have recently been approved for older adults and pregnant women, vaccine development for infants remains challenging due to the risk of vaccine-enhanced disease. Understanding immunological differences between target groups is essential for improving vaccination strategies, but no clear correlates of protection have been identified yet. Antibody Fc-mediated effector functions may play an important role. In a cohort of 24-month old children and adults (n=46 per group), we assessed RSV-specific IgG/IgA levels, IgG subclasses, avidity, Fc glycosylation, and neutralization, antibody-dependent NK cell activation (ADNKA), cellular phagocytosis (ADCP), and complement deposition (ADCD). Compared to children, antibodies from adults showed enhanced functionality. Furthermore, RSV-specific antibodies displayed differences in avidity and glycosylation patterns between the two groups, which might relate to differences in the number of previous exposures. Importantly, our data strongly suggest that IgG Fc afucosylation drives enhanced ADNKA capacity of RSV-specific antibodies. Our data provide a detailed overview of similarities and differences between the RSV-specific antibodies in children and adults. This information will support the ongoing quest for correlates of protection and the design of future vaccination strategies in different target populations.

INSTRUMENT(S):

ORGANISM(S): Homo Sapiens (human)

TISSUE(S): Blood Serum

SUBMITTER: Wenjun Wang

LAB HEAD: Wenjun Wang

PROVIDER: PXD069590 | Pride | 2025-11-05

REPOSITORIES: Pride

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	IgG1_SILuMAb_glycopeptides.txt	Txt
	IgG_trypsin.txt	Txt
	LaCyTools_GlycoDash.zip	Other
	Pilot_study_layout.xlsx	Xlsx
	SILuMAb_GPS_peptide.txt	Txt

Items per page:

1 - 5 of 12

Similar Datasets

Fc glycosylation status of Vi vaccine-induced antibodies following polysaccharide or conjugate Salmonella Typhi vaccine in UK adults and Nepalese children

Project description:Conjugate vaccine against typhoid fever has been shown to be safe and effective in field trials. The mechanism through which the vaccine protects remains elusive. Recent data have implicated antibody glycosylation, and specifically afucosylated antibodies, as an important factor in vaccine-induced effector function for a range of viral infections. Here, we studied IgG glycosylation after conjugate vaccine in a UK cohort, who were then challenged with virulent S.typhi, and among Nepalese children living in a typhoid endemic region. We compared vaccine-induced responses to another licensed typhoid polysaccharide vaccine and correlated these measures with antibody-dependent function to understand if a vaccine against a bacterial infection elicited similar glycosylation/function associations as has been seen for viral infections. Robust antigen-specific IgG Fc galactosylation and sialylation modifications were induced by both polysaccharide and tetanus toxoid-conjugated Salmonella Typhi vaccines in UK adults. These modifications were not able to differentiate controlled human infection model (CHIM) participants who became ill after ingestion of virulent S.typhi from those who remained well after infection. However, among those who did become ill, disease severity was associated with a distinct glycosylation profile. Interestingly, both vaccines induced vaccine-specific IgG1 antibodies that were more fucosylated than total circulating IgG1 and these were not associated with a particular functional profile. While bulk IgG glycosylation was different between Nepalese children and UK adults, vaccination with the Vi-tetanus toxoid-conjugate vaccine resulted in similar Vi-specific IgG glycosylation profiles 28 days after vaccination in both cohorts.

2024-05-30 | PXD037251 | Pride

Fc glycosylation status of Vi vaccine-induced antibodies

2024-05-30 | PXD037239 | Pride

Anti-SARS-CoV-2 antibodies elicited by COVID-19mRNA vaccine exhibits a unique glycosylation pattern

Project description:Messenger RNA-based vaccines against COVID-19 induce a robust anti-SARS-CoV-2 antibody response with potent viral neutralization activity. Antibody effector functions is determined by its constant region subclasses as well as by its glycosylation patterns, but their role in vaccine efficacy is not well understood. Moreover, whether vaccination induce antibodies with similar Fc structures and protection potential as in COVID-19 patients remains unclear. Here, we analyzed BNT162b2 vaccine-induced IgG subclass distribution and Fc glycosylation patterns, as well as their potential to drive effector function via Fc-gamma receptors and complement pathways. We identified a unique Fc composition of these antiviral protein antibodies that is distinct from COVID-19 patients and convalescences. Vaccine-induced anti-spike SARS-CoV-2 IgG displayed a pro-inflammatory Fc profile and superior Fab- and Fc-mediated function, as compared to antibodies generated during natural viral infection. Moreover, differences in the kinetics of IgG Fc structure formation and their engagement with immune receptors were observed between different age groups. These data highlight the heterogeneity of the IgG Fc response to SARS-CoV-2 infection and vaccination and suggest that they differently support long-lasting protection.

2021-11-29 | PXD029321 | Pride

Afucosylated broadly neutralizing antibodies enhance clearance of HIV-1 infected cells through NK cell mediated killing

Project description:A series of monoclonal antibodies (mAbs) against human immune deficiency virus (HIV) were prepared utilizing different variable regions targeting HIV epitopes in combination with glycoengineering to produce mAbs with low Fc fucosylation. This dataset pertains to the Fc N-glycosylation analysis of these mAbs.

2024-07-30 | PXD053363 | Pride

Project description:Sub-Neutralizing Levels of Antibodies against RSV F Protein Enhance RSV Infection via Fc and Fc gamma Recptor interactions

| PRJNA1271456 | ENA

Mass spectrometric analysis of Rheumatoid factor

Project description:Rheumatoid factor are autoantibodies that are found in +/- two thirds of patients with rheumatoid arthritis, a chronic autoimmune disease characterized by inflamed, swollen joints. They consist of polyclonal antibodies that target the Fc part of IgG. The antibodies are not highly specific for rheumatoid arthritis and clinical assays to measure rheumatoid factor are poorly harmonized. We studied rheumatoid factor using a mass-spectrometry-based approach in seropositive, seronegative rheumatoid arthritis patients and in disease controls. Rheumatoid factor was captured on Fc coated microwell plates, isolated, digested into peptides and analyzed by liquid chromatography tandem mass spectrometry. Principal component analysis and sparse partial least squares discriminant analysis showed that peptides derived from seropositive rheumatoid arthritis patients clustered away from the controls. Mass spectrometry analysis revealed framework region-derived and variable region-derived peptides that were enriched in rheumatoid factor positive sera. However, mass spectrometry de novo sequencing failed to sequence the majority of unidentified peptides. Furthermore, mass spectrometry analysis revealed different rheumatoid factor isotypes. In addition to IgM, also IgA and IgG isotypes were observed. In conclusion, mass spectrometry is able to capture the complexity and isotypes of rheumatoid factor autoantibodies, but advances in de novo sequencing are needed to fully characterize the variable part of the antibodies.

2025-10-08 | PXD063283 | Pride

Epitope mapping of potential novel immunogenic proteins of Campylobacter jejuni NCTC 11168

Project description:A number of seven proteins were selected during immunoscreening and further analyses. The proteins were in silico divided into overlapping 15-mer oligopeptides with an overlap of 11 residues. The microarrays were incubated with different antibodies to C. jejuni, Escherichia coli and Salmonella enterica. Each microarray was separated into three individual incubation chambers using ProPlate 3-Well modules. Within each incubation chamber, each peptide was spotted in triplicate with the controls spotted nine times each. The controls included human-IgG, rabbit-IgG, mouse-IgG and myelin basal protein (MBP). Each chamber was incubated independently using different polyclonal antibodies to C. jejuni, and for specificity testing, with an antibody to E. coli or S. enterica. Thus, samples 4_1, 4_2, 5_1 and 5_2 represent epitope mapping of three proteins with C. jejuni antibodies, while 6_1, 6_2, 7_1 and 7_2 represent the data after incubation with an E. coli antibody investigating unspecific interactions of the antibody to the potential linear epitopes from C. jejuni. Finally, for four different proteins from C. jejuni, the set two indicated by S2 was performed. Here, S2_6_1, S2_7_1, S2_7_2, S2_8_1 and S2_8_2 indicate epitope mapping after incubation with antibodies to C. jejuni, while the remaining samples were performed to test these latter 4 proteins for specificity by incubation with antibody to S. enterica.

2013-04-06 | E-GEOD-45542 | biostudies-arrayexpress

Epitope Mapping of potential novel immunogenic proteins of Klebsiella pneumoniae MGH 78578

Project description:A number of six proteins were selected during immunoscreening and further analyses. The proteins were divided in silico into overlapping 15-mer oligopeptides with an overlap of 11 residues. The microarrays were incubated with different antibodies to K. pneumoniae, C. jejuni and S. aureus. Each microarray was seperated into three individual incubation chambers using ProPlate 3-Well modules. Within each incubation chamber each peptide was spotted in triplicate with the controls spotted nine times each. The controls included Human-IgG, Rabbit-IgG, Mouse-IgG and Myelin Basal Protein. Each chamber was incubated independently using different polyclonal antibodies to K. pneumoniae and for specificity testing with antibodies to C. jejuni or S. aureus. Thus, samples 2_1, 2_2, 3_1 and 3_2 represent epitope mapping of three proteins and S2_5_1, S2_5_2, S2_6_1 and S2_6_2 epitope mapping of three different proteins with K. pneumoniae antibodies, while 4_1, 4_2, 5_1 and 5_2 represent specificity assays for the first set of proteins (using C. jejuni and S. aureus antibodies) and S2_1_1, S2_1_2, S2_2_1, S2_2_2 (C. jejuni AB) as well as S2_7_1, S2_7_2, S2_8_1, S2_8_2 (S. aureus AB) for the second set of proteins.

2014-02-02 | E-GEOD-52537 | biostudies-arrayexpress

Investigation of the FcRn:IgG interaction by HDX-MS

Project description:Immunoglobulin Gs (IgGs) have become highly successful drug scaffolds by combining very specific target binding with the ability to induce cellular cytotoxicity. Of further advantage, IgGs possess unusually long half-lives in the blood (2-3 week). IgGs achieve such extraordinary half-lives through a pH-dependent interaction with the Neonatal Fc receptor (FcRn) whereby IgGs are recycled. No high-resolution structure of FcRn in complex with a full-length IgG is available, and the interaction was long thought to be mediated solely via the IgG Fc. However, some IgGs with identical Fc parts, but different Fab domains, exhibit different half-lives, suggesting involvement of the Fab domains in FcRn binding. Here, we have employed a combination of HDX-MS and cross-linking MS (XL-MS) to explore the interaction of a full-length IgG with FcRn. HDX-MS and XL-MS analysis confirms an interaction between FcRn and the Fc-domain of IgGs, as a reduction of HDX was observed in both the Fc-domain and FcRn upon complex formation, and three cross-links were identified between FcRn and the Fc-domain. However, FcRn-induced changes in HDX were also observed in the Fab domains, supported by multiple cross-links between the Fab domains and the C-terminal α3 domain of FcRn. Our results thus provide direct evidence for a Fab-FcRn interaction. We envision that these result could advance the engineering of therapeutic IgGs with tailored pharmacokinetics and enhanced efficacy.

2024-12-02 | PXD044285 | Pride

Profiling of Subclass-Specific IgG Glycosylation in Gastric Cancer by nanoLC-ESI-MS/MS

Project description:Background:Gastric cancer (GC) is one of the most aggressive gastrointestinal malignancy and leading cause of cancer related deaths worldwide,warranting the urgent discovery of biomarkers for early detection. IgG glycosylation is strongly related to disease progression and specific IgG glycans have been regarded as the next-generation biomarker, whereas it is rarly studied on the association between subclass-specific IgG glycosylation profile and GC progression. Methods:A total of 141 individuals were enrolled and randomly sorted into discovery set consisting of normal (N=30) and cancer patients (N=20), and validation set including controls (N=30), benign (N=25) and cancer (N=36).IgG glycopeptides were tryptic digested and enrichmed by microcrystalline cellulose based solid phase extraction.Subclass-specific IgG N-glycosylation was analyzed by nanoLC-MS/MS. Results:It was found that GC progression was associated with increased sialylation and decreased bisection of IgG2, as well as substantially decreased sialylation of IgG1 and increased galactosylation of IgG3/4.Further analysis of individual glycopeptides showed the changes of particular glycosylation of IgGwere reflected by the specific glycans taht could apparently distinguish different stages of gastric disease patients from normal. Conclusions:Different subclasses of IgG glycosylation were differentially expressed in GC, specific IgG glycopeptides could be promising biomarker for early detection of GC patients.

2025-05-06 | PXD027475 | Pride